1-11 of 11
Rahul Aggarwal
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Effective Treatment of Disseminated Prostate Cancer Using CD46-Targeted 225Ac Therapy

Open Access
Anil P. Bidkar, Robin Peter, Anju Wadhwa, Kondapa Naidu Bobba, Scott Bidlingmaier, Niranjan Meher, Jonathan Chou, Nancy Greenland, Chandrashekhar Dasari, Shubhankar Naik, Athira Raveendran, Megha Basak, Juan Antonio Camara Serrano, Veronica Steri, Scott Kogan, Adam Oskowitz, Jiang He, David M. Wilson, Rahul Aggarwal, Renuka Sriram, Henry F. VanBrocklin, Youngho Seo, Bin Liu, Robert R. Flavell
Journal: Clinical Cancer Research
Clin Cancer Res OF1–OF15.
https://doi.org/10.1158/1078-0432.CCR-24-2850
Published: 11 March 2025
View articletitled, Effective Treatment of Disseminated Prostate Cancer Using CD46-Targeted 225Ac Therapy
Open the PDF for Effective Treatment of Disseminated Prostate Cancer Using CD46-Targeted 225Ac Therapy in another window
Includes: Supplementary data
Journal Articles

Framework for the Pathology Workup of Metastatic Castration-Resistant Prostate Cancer Biopsies

Available to Purchase
Michael C. Haffner, Michael J. Morris, Chien-Kuang C. Ding, Erolcan Sayar, Rohit Mehra, Brian Robinson, Lawrence D. True, Martin Gleave, Tamara L. Lotan, Rahul Aggarwal, Jiaoti Huang, Massimo Loda, Peter S. Nelson, Mark A. Rubin, Himisha Beltran
Journal: Clinical Cancer Research
Clin Cancer Res (2025) 31 (3): 466–478.
https://doi.org/10.1158/1078-0432.CCR-24-2061
Published: 03 February 2025
View articletitled, Framework for the Pathology Workup of Metastatic Castration-Resistant Prostate Cancer Biopsies
Open the PDF for Framework for the Pathology Workup of Metastatic Castration-Resistant Prostate Cancer Biopsies in another window
Includes: Supplementary data
Journal Articles

Treatment of Prostate Cancer with CD46-targeted 225Ac Alpha Particle Radioimmunotherapy

Open Access
Anil P. Bidkar, Sinan Wang, Kondapa Naidu Bobba, Emily Chan, Scott Bidlingmaier, Emily A. Egusa, Robin Peter, Umama Ali, Niranjan Meher, Anju Wadhwa, Suchi Dhrona, Chandrashekhar Dasari, Denis Beckford-Vera, Yang Su, Ryan Tang, Li Zhang, Jiang He, David M. Wilson, Rahul Aggarwal, Henry F. VanBrocklin, Youngho Seo, Jonathan Chou, Bin Liu, Robert R. Flavell
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (10): 1916–1928.
https://doi.org/10.1158/1078-0432.CCR-22-3291
Published: 15 May 2023
View articletitled, Treatment of Prostate Cancer with CD46-targeted 225Ac Alpha Particle Radioimmunotherapy
Open the PDF for Treatment of Prostate Cancer with CD46-targeted 225Ac Alpha Particle Radioimmunotherapy in another window
Includes: Supplementary data
Journal Articles

Intrinsic Molecular Subtypes of Metastatic Castration-Resistant Prostate Cancer

Available to Purchase
Eric Feng, Nicholas R. Rydzewski, Meng Zhang, Arian Lundberg, Matthew Bootsma, Kyle T. Helzer, Joshua M. Lang, Rahul Aggarwal, Eric J. Small, David A. Quigley, Martin Sjöström, Shuang G. Zhao
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (24): 5396–5404.
https://doi.org/10.1158/1078-0432.CCR-22-2567
Published: 15 December 2022
View articletitled, Intrinsic Molecular Subtypes of Metastatic Castration-Resistant Prostate Cancer
Open the PDF for Intrinsic Molecular Subtypes of Metastatic Castration-Resistant Prostate Cancer in another window
Includes: Supplementary data
Journal Articles

Phase Ib Study of the BET Inhibitor GS-5829 as Monotherapy and Combined with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer

Open Access
Rahul Aggarwal, Alexander N. Starodub, Brian D. Koh, Guan Xing, Andrew J. Armstrong, Michael A. Carducci
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (18): 3979–3989.
https://doi.org/10.1158/1078-0432.CCR-22-0175
Published: 15 September 2022
View articletitled, Phase Ib Study of the BET Inhibitor GS-5829 as Monotherapy and Combined with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer
Open the PDF for Phase Ib Study of the BET Inhibitor GS-5829 as Monotherapy and Combined with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer in another window
Includes: Supplementary data
Journal Articles

CUB Domain-Containing Protein 1 (CDCP1) Is a Target for Radioligand Therapy in Castration-Resistant Prostate Cancer, including PSMA Null Disease

Available to Purchase
Ning Zhao, Shalini Chopra, Kai Trepka, Yung-Hua Wang, Sasank Sakhamuri, Nima Hooshdaran, Hyunjung Kim, Jie Zhou, Shion A. Lim, Kevin K. Leung, Emily A. Egusa, Jun Zhu, Li Zhang, Adam Foye, Renuka Sriram, Emily Chan, Youngho Seo, Felix Y. Feng, Eric J. Small, Jonathan Chou, James A. Wells, Rahul Aggarwal, Michael J. Evans
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (14): 3066–3075.
https://doi.org/10.1158/1078-0432.CCR-21-3858
Published: 15 July 2022
View articletitled, CUB Domain-Containing Protein 1 (CDCP1) Is a Target for Radioligand Therapy in Castration-Resistant Prostate Cancer, including PSMA Null Disease
Open the PDF for CUB Domain-Containing Protein 1 (CDCP1) Is a Target for Radioligand Therapy in Castration-Resistant Prostate Cancer, including PSMA Null Disease in another window
Includes: Supplementary data
Journal Articles

A Phase Ib/II Study of the CDK4/6 Inhibitor Ribociclib in Combination with Docetaxel plus Prednisone in Metastatic Castration-Resistant Prostate Cancer

Available to Purchase
Ivan de Kouchkovsky, Arpit Rao, Benedito A. Carneiro, Li Zhang, Catriona Lewis, Audrey Phone, Eric J. Small, Terence Friedlander, Lawrence Fong, Pamela L. Paris, Charles J. Ryan, Russell Z. Szmulewitz, Rahul Aggarwal
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (8): 1531–1539.
https://doi.org/10.1158/1078-0432.CCR-21-4302
Published: 14 April 2022
View articletitled, A Phase Ib/II Study of the CDK4/6 Inhibitor Ribociclib in Combination with Docetaxel plus Prednisone in Metastatic Castration-Resistant Prostate Cancer
Open the PDF for A Phase Ib/II Study of the CDK4/6 Inhibitor Ribociclib in Combination with Docetaxel plus Prednisone in Metastatic Castration-Resistant Prostate Cancer in another window
Includes: Supplementary data
Journal Articles

BET Bromodomain Inhibition Blocks an AR-Repressed, E2F1-Activated Treatment-Emergent Neuroendocrine Prostate Cancer Lineage Plasticity Program

Open Access
Dae-Hwan Kim, Duanchen Sun, William K. Storck, Katherine Welker Leng, Chelsea Jenkins, Daniel J. Coleman, David Sampson, Xiangnan Guan, Anbarasu Kumaraswamy, Eva S. Rodansky, Joshua A. Urrutia, Jacob A. Schwartzman, Chao Zhang, Himisha Beltran, Mark P. Labrecque, Colm Morrissey, Jared M. Lucas, Ilsa M. Coleman, Peter S. Nelson, Eva Corey, Samuel K. Handelman, Jonathan Z. Sexton, Rahul Aggarwal, Wassim Abida, Felix Y. Feng, Eric J. Small, Daniel E. Spratt, Armand Bankhead, III, Arvind Rao, Emily M. Gesner, Sarah Attwell, Sanjay Lakhotia, Eric Campeau, Joel A. Yates, Zheng Xia, Joshi J. Alumkal
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (17): 4923–4936.
https://doi.org/10.1158/1078-0432.CCR-20-4968
Published: 01 September 2021
View articletitled, BET Bromodomain Inhibition Blocks an AR-Repressed, E2F1-Activated Treatment-Emergent Neuroendocrine Prostate Cancer Lineage Plasticity Program
Open the PDF for BET Bromodomain Inhibition Blocks an AR-Repressed, E2F1-Activated Treatment-Emergent Neuroendocrine Prostate Cancer Lineage Plasticity Program in another window
Includes: Supplementary data
Journal Articles

Molecular Imaging of Prostate Cancer Targeting CD46 Using ImmunoPET

Available to Purchase
Sinan Wang, Jun Li, Jun Hua, Yang Su, Denis R. Beckford-Vera, Walter Zhao, Mayuri Jayaraman, Tony L. Huynh, Ning Zhao, Yung-hua Wang, Yangjie Huang, Fujun Qin, Sui Shen, Daniel Gioeli, Robert Dreicer, Renuka Sriram, Emily A. Egusa, Jonathan Chou, Felix Y. Feng, Rahul Aggarwal, Michael J. Evans, Youngho Seo, Bin Liu, Robert R. Flavell, Jiang He
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (5): 1305–1315.
https://doi.org/10.1158/1078-0432.CCR-20-3310
Published: 01 March 2021
View articletitled, Molecular Imaging of Prostate Cancer Targeting CD46 Using ImmunoPET
Open the PDF for Molecular Imaging of Prostate Cancer Targeting CD46 Using ImmunoPET in another window
Includes: Supplementary data
Journal Articles

Autoantibody Landscape in Patients with Advanced Prostate Cancer

Available to Purchase
William S. Chen, Winston A. Haynes, Rebecca Waitz, Kathy Kamath, Agustin Vega-Crespo, Raunak Shrestha, Minlu Zhang, Adam Foye, Ignacio Baselga Carretero, Ivan Perez Garcilazo, Meng Zhang, Shuang G. Zhao, Martin Sjöström, David A. Quigley, Jonathan Chou, Tomasz M. Beer, Matthew Rettig, Martin Gleave, Christopher P. Evans, Primo Lara, Kim N. Chi, Robert E. Reiter, Joshi J. Alumkal, Alan Ashworth, Rahul Aggarwal, Eric J. Small, Patrick S. Daugherty, Antoni Ribas, David Y. Oh, John C. Shon, Felix Y. Feng
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (23): 6204–6214.
https://doi.org/10.1158/1078-0432.CCR-20-1966
Published: 01 December 2020
View articletitled, Autoantibody Landscape in Patients with Advanced Prostate Cancer
Open the PDF for Autoantibody Landscape in Patients with Advanced Prostate Cancer in another window
Includes: Supplementary data
Journal Articles

First-in-Human Phase I Study of GSK2126458, an Oral Pan-Class I Phosphatidylinositol-3-Kinase Inhibitor, in Patients with Advanced Solid Tumor Malignancies

Free
Pamela Munster, Rahul Aggarwal, David Hong, Jan H.M. Schellens, Ruud van der Noll, Jennifer Specht, Petronella O. Witteveen, Theresa L. Werner, E. Claire Dees, Emily Bergsland, Neeraj Agarwal, Joseph F. Kleha, Michael Durante, Laurel Adams, Deborah A. Smith, Thomas A. Lampkin, Shannon R. Morris, Razelle Kurzrock
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (8): 1932–1939.
https://doi.org/10.1158/1078-0432.CCR-15-1665
Published: 14 April 2016
View articletitled, First-in-Human Phase I Study of GSK2126458, an Oral Pan-Class I Phosphatidylinositol-3-Kinase Inhibitor, in Patients with Advanced Solid Tumor Malignancies
Open the PDF for First-in-Human Phase I Study of GSK2126458, an Oral Pan-Class I Phosphatidylinositol-3-Kinase Inhibitor, in Patients with Advanced Solid Tumor Malignancies in another window
Includes: Supplementary data